Barclays’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$41.9M Buy
300,500
+50,000
+20% +$7M 0.01% 795
2025
Q4
$30.7M Hold
250,500
0.01% 1012
2025
Q3
$27.8M Hold
250,500
0.01% 1045
2025
Q2
$27.8M Sell
250,500
-49,300
-16% -$5.25M 0.01% 954
2025
Q1
$33.6M Buy
299,800
+8,700
+3% +$898K 0.01% 809
2024
Q4
$26.9M Buy
291,100
+176,500
+154% +$15.9M 0.01% 949
2024
Q3
$9.61M Sell
114,600
-119,700
-51% -$9.13M ﹤0.01% 1512
2024
Q2
$16.1M Buy
234,300
+171,032
+270% +$11.4M ﹤0.01% 1012
2024
Q1
$4.63M Sell
63,268
-40,132
-39% -$3.09M ﹤0.01% 1909
2023
Q4
$8.38M Buy
103,400
+50,600
+96% +$3.94M ﹤0.01% 1649
2023
Q3
$3.96M Sell
52,800
-121,600
-70% -$9.35M ﹤0.01% 1471
2023
Q2
$13.4M Buy
174,400
+127,200
+269% +$10.1M 0.01% 872
2023
Q1
$3.92M Sell
47,200
-163,200
-78% -$13.5M ﹤0.01% 1719
2022
Q4
$18.1M Buy
+210,400
New +$16.7M 0.01% 938
2022
Q1
Sell
-267,100
Closed -$19.4M 5195
2021
Q4
$19.4M Buy
267,100
+93,500
+54% +$6.44M 0.01% 955
2021
Q3
$12.1M Buy
173,600
+97,500
+128% +$6.85M 0.01% 1089
2021
Q2
$5.24M Sell
76,100
-67,900
-47% -$4.53M ﹤0.01% 1557
2021
Q1
$9.31M Sell
144,000
-272,500
-65% -$17.6M 0.01% 1123
2020
Q4
$24.3M Hold
416,500
0.01% 759
2020
Q3
$26.3M Buy
416,500
+286,600
+221% +$19.9M 0.02% 630
2020
Q2
$9.99M Sell
129,900
-482,100
-79% -$36.9M 0.01% 966
2020
Q1
$45.8M Sell
612,000
-442,500
-42% -$30.6M 0.04% 333
2019
Q4
$68.5M Buy
1,054,500
+597,100
+131% +$38.9M 0.04% 379
2019
Q3
$29M Buy
457,400
+130,300
+40% +$8.52M 0.02% 687
2019
Q2
$22.1M Sell
327,100
-67,200
-17% -$4.42M 0.01% 869
2019
Q1
$25.6M Buy
394,300
+13,900
+4% +$924K 0.02% 716
2018
Q4
$23.8M Sell
380,400
-310,000
-45% -$21.7M 0.02% 670
2018
Q3
$53.3M Buy
690,400
+178,900
+35% +$13.5M 0.04% 388
2018
Q2
$36.2M Sell
511,500
-84,900
-14% -$6M 0.03% 485
2018
Q1
$45M Buy
596,400
+176,200
+42% +$14M 0.03% 459
2017
Q4
$30.1M Sell
420,200
-167,600
-29% -$12.7M 0.02% 600
2017
Q3
$47.6M Buy
587,800
+189,200
+47% +$14.5M 0.05% 310
2017
Q2
$28.2M Sell
398,600
-257,600
-39% -$17.1M 0.03% 458
2017
Q1
$44.6M Sell
656,200
-273,800
-29% -$19.3M 0.05% 285
2016
Q4
$66.6M Buy
930,000
+271,800
+41% +$20.2M 0.07% 213
2016
Q3
$52.1M Buy
658,200
+211,700
+47% +$17.2M 0.06% 248
2016
Q2
$37.2M Sell
446,500
-112,300
-20% -$9.97M 0.05% 321
2016
Q1
$50.9M Sell
558,800
-76,200
-12% -$6.87M 0.08% 214
2015
Q4
$64.1M Sell
635,000
-729,400
-53% -$75.9M 0.08% 215
2015
Q3
$134M Buy
1,364,400
+420,800
+45% +$46.7M 0.16% 99
2015
Q2
$110M Sell
943,600
-604,100
-39% -$66M 0.12% 131
2015
Q1
$152M Buy
1,547,700
+376,300
+32% +$38.2M 0.17% 92
2014
Q4
$110M Sell
1,171,400
-60,000
-5% -$6.21M 0.11% 153
2014
Q3
$131M Sell
1,231,400
-1,072,400
-47% -$105M 0.13% 117
2014
Q2
$189M Sell
2,303,800
-189,400
-8% -$14.7M 0.2% 62
2014
Q1
$175M Buy
2,493,200
+2,002,700
+408% +$157M 0.2% 80
2013
Q4
$36.8M Sell
490,500
-843,600
-63% -$58.7M 0.04% 459
2013
Q3
$82.7M Sell
1,334,100
-131,400
-9% -$7.85M 0.1% 168
2013
Q2
$75.1M Buy
+1,465,500
New +$76.4M 0.09% 164

Other funds holding GILD

Barclays's GILD Position: Q1 2026 in Review

Barclays reduced its Gilead Sciences (GILD) stake by 42% in Q1 2026, selling an estimated $537M and leaving 5,282,196 shares worth $736M. The position accounts for 0.18% of the portfolio, ranked #85.

Barclays first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.12B in Q4 2025. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Barclays held 5,282,196 shares of Gilead Sciences worth $736M as of Q1 2026.
  • Barclays sold 3,833,287 Gilead Sciences shares in Q1 2026, an estimated $537M.
  • Gilead Sciences made up 0.18% of Barclays's portfolio in Q1 2026, its #85 holding.
  • Barclays first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Gilead Sciences position peaked at $1.12B in Q4 2025.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.